

14. Meissner T, Marquardt J, Cobo-Vuilleumier N et al. Diagnostic difficulties in glucokinase hyperinsulinism. Horm Metab Res 2009;41:320-6.
15. Suchi M, Thornton PS, Adzick NS et al. Congenital hyperinsulinism. Am J Surg Pathol 2004;28:1326-35.
16. Bellanné-Chantelot C, Saint-Martin C, Ribeiro MJ et al. ABCC8 and KCNJ11 molecular spectrum of 109 patients with diazoxide-unresponsive congenital hyperinsulinism. J Med Genet 2010;47:752-9.
17. Rahier J, Guiot Y, Sempoux C. Persistent hyperinsulinaemic hypoglycaemia of infancy: a heterogeneous syndrome unrelated to nesidioblastosis. Arch Dis Child Fetal Neonatal Ed 2000;82:F108-12.
18. Capito C, de Lonlay P, Verkarre V et al. The surgical management of atypical forms of congenital hyperinsulinism. Semin Pediatr Surg 2011;20:54-55.
19. Clayton P, Eaton S, Aynsley-Green A et al. Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of β-oxidation in insulin secretion. J Clin Invest 2001;108:457-65.
20. Otonkoski T, Kämänen N, Ustinov J et al. Physical exercise-induced hyperinsulinemic hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate-induced insulin release. Diabetes 2003;52:199-204.
21. González-Barroso MM, Giurgea I, Bouillaud F et al. Mutations in UCP2 in congenital hyperinsulinism reveal a role for regulation of insulin secretion. PLoS One 2008;3:1-8.
22. Flanagan SE, Kapoor RR, Mali G et al. Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. Eur J Endocrinol 2010;162:987-92.
23. Magge SN, Shyng SL, MacMullen C et al. Familial leucine-sensitive hypoglycemia of infancy due to a dominant mutation of the beta-cell sulfonylurea receptor. J Clin Endocrinol Metab 2004;89:4450-6.
24. de Lonlay P, Giurgea I, Sempoux C et al. Dominantly inherited hyperinsulinaemic hypoglycaemia. J Inher Metab Dis 2005;28:267-76.
25. Kassem SA, Ariel I, Thornton PS et al. Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes 2000;49:1325-33.
26. Pinney SE, MacMullen C, Becker S et al. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest 2008;118:2877-86.
27. Hussain K, Flanagan SE, Smith VV et al. An ABCC8 gene mutation and mosaic uniparental isodisomy resulting in atypical diffuse congenital hyperinsulinism. Diabetes 2008;57:259-63.
28. Seghers V, Nakazaki M, DeMayo F et al. Sur1 knockout mice. J Biol Chem 2000;275:9270-7.
29. Bahi-Buisson N, Roze E, Dionisi C et al. Neurological aspects of hyperinsulinism-hyperammonaemia syndrome. Dev Med Child Neurol 2008;50:945-9.
30. Kapoor RR, Flanagan SE, Fulton P et al. Hyperinsulinism-hyperammonaemia syndrome: novel mutations in the GLUD1 gene and genotype-phenotype correlations. Eur J Endocrinol 2009;161:731-5.
31. Kapoor RR, James C, Flanagan SE et al. 3-hydroxyacyl-coenzyme A dehydrogenase deficiency and hyperinsulinemic hypoglycemia: characterization of a novel mutation and severe dietary protein sensitivity. J Clin Endocrinol Metab 2009;94:2221-5.
32. Kaur S, Kulkarni KP, Kochar IP. Severe dietary protein sensitivity and hyperinsulinemic hypoglycemia in a patient with heterozygous mutation in HADH gene. J Pediatr Endocrinol Metab 2010;23:953-5.
33. Li C, Chen P, Palladino A et al. Mechanism of hyperinsulinism in short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency involves activation of glutamate dehydrogenase. J Biol Chem 2010;285:31806-18.
34. Dullaart RP, Hoogenberg K, Rouwé CW et al. Family with autosomal dominant hyperinsulinism associated with A456V mutation in the glucokinase gene. J Intern Med 2004;255:143-5.
35. Kassem S, Heyman M, Glaser B et al. Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl Med 2010;362:1348-50.
36. Meissner T, Friedmann B, Okun JG et al. Massive insulin secretion in response to anaerobic exercise in exercise-induced hyperinsulinism. Horm Metab Res 2005;37:690-4.
37. Kapoor RR, Locke J, Colclough K et al. Persistent hyperinsulinemic hypoglycemia and maturity-onset diabetes of the young due to heterozygous HNF4A mutations. Diabetes 2008;57:1659-63.
38. Højlund K, Hansen T, Lajer M et al. A novel syndrome of autosomal-dominant hyperinsulinemic hypoglycemia linked to a mutation in the human insulin receptor gene. Diabetes 2004;53:1592-8.
39. de Lonlay P, Simon A, Galmiche-Rolland L et al. Neonatal hyperinsulinism: clinicopathologic correlation. Hum Pathol 2007;38:387-399.
40. Christesen HT, Bruun MF, Christoffersen SH et al. Kongenit hyperinsulinisme – diagnostik og behandling. Ugeskr Læger 2011;173:3020-5.



LÆGEMIDDELSTYRELSEN

TILSKUDET TIL LÆGEMIDLER

Lægemiddelstyrelsen meddeler, at der pr. 14. november 2011 ydes generelt uklarert tilskud efter sundhedslovens § 144 til følgende lægemidler:

- (N-02-CC-05) Almográn tabletter*, Abacus Medicine ApS
- (C-08-CA-01) Amlori tabletter*, Orifarm Generics A/S
- (S-01-ED-51) DuoTrav øjendråber*, Abacus Medicine ApS
- (A-10-BD-08) Eucreas tabletter*, Orifarm A/S
- (I-02-BG-06) Exemestan »Sandoz« tabletter*, Sandoz A/S
- (N-05-AX-13) Invega depottabletter*, Abacus Medicine ApS
- (N-03-AX-14) Levetiracetam »Accord« tabletter*, Accord Healthcare AB
- (N-03-AX-14) Levetiracetam »Actavis« tabletter*, Actavis A/S
- (N-02-CC-04) Maxalt Lingua smeltatabletter*, A-Pharma ApS
- (H-01-CC-01) Orgalutran injektionsvæske*, Orifarm A/S

(N-05-AX-08) Risopolept Consta depotinjektionsvæske, 2care4 ApS

(R-03-AK-06) Seretide Evohaler inhalationsspray*, Orifarm A/S

Der ydes generelt klausuleret tilskud til følgende lægemidler:

(J-07-BC-01) Engerix B injektionsvæske*, Orifarm A/S

Lægemidlet er klausuleret til personer, der opfylder følgende sygdomsklausul: Personer med Downs syndrom. Personer utsat for relevante stikuheld. En betingelse for at opnå tilskud er, at lægen har skrevet »tilskud« på receptionen.

Denne bestemmelse træder i kraft den 14. november 2011.

*) Omfattet af tilskudsprissystemet.